YD Bio Ltd YDES
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.12
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $596.8K | $510.4K | $350.1K | — |
| Cost of revenue | $429.4K | $355.0K | $196.7K | — |
| Gross profit | $167.4K | $155.4K | $153.4K | — |
| R&D | $1.6M | $491.4K | — | — |
| SG&A | $3.7M | $1.1M | $153.1K | — |
| Total operating expenses | $5.4M | $1.6M | $163.3K | — |
| Operating income | -$5.3M | -$1.5M | -$9.8K | — |
| Interest expense | — | $772 | $2.1K | — |
| Pre-tax income | -$8.3M | -$1.4M | $17.6K | — |
| Income tax | $1.5K | $25.1K | $4.1K | — |
| Net income | -$8.3M | -$1.4M | $13.6K | — |
| EPS, basic | -0.12 | -0.02 | 0.00 | — |
| EPS, diluted | -0.12 | -0.02 | 0.00 | — |
| Shares, diluted (wtd. avg.) | 66.7M | 64.7M | 64.7M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $6.0M | $3.1M | $87.1K | $30.1K |
| Receivables | $167.5K | $86.6K | — | — |
| Inventory | $1.9M | $37.3K | — | — |
| Total current assets | $9.7M | $3.5M | — | — |
| Property, plant and equipment | $59.3K | $64.4K | — | — |
| Other intangibles | $2.6M | $2.7M | — | — |
| Total assets | $13.8M | $6.9M | — | — |
| Accounts payable | $413.3K | $26.9K | — | — |
| Total current liabilities | $1.6M | $263.1K | — | — |
| Total liabilities | $16.6M | $274.0K | — | — |
| Retained earnings | -$10.2M | -$1.9M | — | — |
| Total equity | -$2.9M | $6.6M | $23.0K | $9.3K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$6.6M | -$1.2M | -$55.7K | — |
| Depreciation and amortisation | $16.2K | $10.2K | $2.5K | — |
| Capital expenditure | $1.4M | $74.9K | $290 | — |
| Investing cash flow | -$1.4M | -$2.9M | -$290 | — |
| Financing cash flow | $10.9M | $7.1M | $113.9K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-061106.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | $350.1K | $510.4K | $596.8K |
| Gross profit | — | $153.4K | $155.4K | $167.4K |
| Net income | — | $13.6K | -$1.4M | -$8.3M |
Others in SIC 8071
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| NTRA | Natera, Inc. | $58.23B | — | 35.9% |
| DGX | QUEST DIAGNOSTICS INC | $26.70B | 27.6x | 11.8% |
| LH | LABCORP HOLDINGS INC. | $26.68B | 31.4x | 7.2% |
| GH | Guardant Health, Inc. | $22.69B | — | 32.9% |
| CAI | Caris Life Sciences, Inc. | $9.04B | — | 97.0% |
| GRAL | GRAIL, Inc. | $5.92B | — | 17.2% |
| RDNT | RadNet, Inc. | $5.54B | — | 11.5% |
| BLLN | BillionToOne, Inc. | $5.00B | 769.8x | 100.0% |